The year 2018 was a banner year for biosimilars, with the number of FDA-approved biosimilar products nearly doubling, and with major policy, business, and regulatory developments that moved the biosimilars marketplace forward. Here are 5 of the top developments in biosimilars for the past year, as reported by The Center for Biosimilars®, a sister site of The American Journal of Managed Care®.